Technetium and Rhenium in Nuclear Medicine
Technetium and Rhenium in Nuclear Medicine
批准号:
7342139
负责人:
Alun Gareth Jones
金额:
$56.39万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1977
资助国家:
美国
项目状态:
已结题
起止时间:
1977-02-01 至 2010-12-31
关键词:
AffinityAnimal ModelAreaBehaviorBiological AssayBrainBudgetsCellsChemicalsChemistryClinicClinicalComplexCountryCoupledDetectionDevelopmentDiscipline of Nuclear MedicineDiseaseDrug KineticsEvaluationFacultyFundingFutureGrantGrowthHuman bodyImageImaging TechniquesInorganic ChemistryInstitutesIntentionLeadLigandsLongitudinal StudiesLungMalignant NeoplasmsMalignant neoplasm of prostateMassachusettsMetalsMonitorNeuraxisNeurotransmittersNew AgentsOxidation-ReductionPharmacodynamicsPlayPliabilityPublic HealthPurposeRadioisotopesRadiopharmaceuticalsResearchResearch PersonnelResolutionResourcesRheniumRoleSensory ReceptorsSiteSourceStructure-Activity RelationshipSystemTechnetiumTechnologyTimeTissuesWorkbasecancer imagingdesignimprovedin vivoin vivo Modelmedical schoolsmelanomaoncologypharmacophorepreclinical studypreferenceprogramsreceptorsingle photon emission computed tomographytertiary aminetumortumor growthuptake
中文摘要
本提案中描述的研究是基于99 mTc
在常规临床核医学实践中仍将是重要的放射性核素。主要的推力是
在两个领域开发新的制剂,再加上一些精心挑选的化学研究
旨在增加产品复合物设计的灵活性,从而增加其生物学行为。第一
主要目的是继续评估能够检测存在的锝络合物,
体内恶性黑素瘤。在本周期内,已确定若干潜在候选人,
在黑色素瘤动物模型中显示出显著的摄取,包括转移性扩散到肺的黑色素瘤。一
一种新的高分辨率microSPECT摄像机现在已经使纵向研究成为可能,
这是一项非常有用的能力,将在拟议期间进一步研究。的
第二个主要目标是继续设计对5 HT 1A受体具有亲和力的复合物。来
过去几年来,人们越来越清楚地看到,除了在中央的既定职能外,
神经系统、神经递质系统在癌症的生长和扩散中起着重要作用
在整个人体内。因此,计划测定正常脑和体内模型中的摄取,
前列腺癌,表达这种受体类型的肿瘤的一个例子。寻找高分子配合物
对5-HT 1A受体的亲和性和选择性随着重要的双重靶向治疗的前景而增加。
研究的目的。第三个主要目的是检查化学行为和配体偏好
两种金属核作为目标1和2中使用的Tc/Re(V)氧代核的替代品:
Tc(I)三羰基核心和较少研究的Tc(I)亚硝酰基核心。这种化学反应将在
支持目标1和目标2的工作,因为目标2的核心应在目标1和目标2的设计方面提供更大的灵活性。
用于安装给定生物活性部分的最终平台。恶性黑色素瘤和前列腺癌
都是这个国家严重的公共卫生问题这项工作的目的是开发一种手段,
这些肿瘤在临床上使用非侵入性成像技术。microSPECT成像能力,
小动物模型也可以证明在临床前研究中评估新的
治疗这些疾病。
英文摘要
The research described in this proposal is the continuation of a program based on the premise that 99mTc
will remain an important radionuclide in the practice of routine clinical nuclear medicine. The primary thrust is
the development of new agents in two areas, coupled with some carefully selected chemical studies
intended to add flexibility in the design of the product complexes and, thus, their biologic behavior. The first
major aim is to continue the evaluation of technetium complexes capable of detecting the presence of
malignant melanoma in vivo. Over this current cycle, several potential candidates have been identified as
showing significant uptake in animal models of melanoma, including one of metastatic spread to the lungs. A
new high resolution microSPECT camera has now made possible longitudinal studies that allow monitoring
of tumor growth with time, a highly useful capability that will be pursued further in the proposed period. The
second major aim is to continue designing complexes that have affinity for the 5HT1A receptor. Over the
past few years it has become increasingly clear that, apart from their established function in the central
nervous system, neurotransmitter systems play a significant role in the growth and spread of cancer
throughout the human body. Thus, it is planned to assay uptake in both normal brain and in vivo models of
prostate cancer, an example of tumors that express this receptor type. The search for complexes with high
affinity and selectivity for 5HT1A receptors increases in importance with the prospect of important dual
purposes for the research. The third major aim is to examine the chemical behavior and ligand preferences
of two metal cores as alternatives to the Tc/Re(V) oxo core used in aims 1and 2: the relatively well-studied
Tc(l) tricarbonyl core and the less well-explored Tc(l) nitrosyl core. This chemistry will be conducted in
support of the work in aims 1 and 2 in that the latter cores should provide more flexibility in the design of the
final platform for mounting a given biologically active moiety. Malignant melanoma and prostate cancer are
both serious public health problems in this country. This work is designed to develop a means of detecting
these tumors in the clinic using noninvasive imaging techniques. The microSPECT imaging capability with
small-animal models could also prove useful in preclinical studies assessing the development of new
therapies for these diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE
-
批准号:2088804
-
项目类别:
-
资助金额:$53.07万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE
-
批准号:2633759
-
项目类别:
-
资助金额:$53.67万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
THE CHEMISTRY OF TECHNETIUM RELATED TO NUCLEAR MEDICINE
-
批准号:3172756
-
项目类别:
-
资助金额:$37.6万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE
-
批准号:6512439
-
项目类别:
-
资助金额:$49.34万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
THE CHEMISTRY OF TECHNETIUM RELATED TO NUCLEAR MEDICINE
-
批准号:3172758
-
项目类别:
-
资助金额:$37.81万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
THE CHEMISTRY OF TECHNETIUM RELATED TO NUCLEAR MEDICINE
-
批准号:3172757
-
项目类别:
-
资助金额:$37.29万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
THE CHEMISTRY OF TECHNETIUM RELATED TO NUCLEAR MEDICINE
-
批准号:3172755
-
项目类别:
-
资助金额:$21.38万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE
-
批准号:2856237
-
项目类别:
-
资助金额:$55.13万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE
-
批准号:3482296
-
项目类别:
-
资助金额:$48.2万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE
-
批准号:3482295
-
项目类别:
-
资助金额:$48.39万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
Technetium and Rhenium in Nuclear Medicine
-
批准号:7049207
-
项目类别:
-
资助金额:$59.84万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE
-
批准号:6632909
-
项目类别:
-
资助金额:$50.55万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
Technetium and Rhenium in Nuclear Medicine
-
批准号:7743729
-
项目类别:
-
资助金额:$58.79万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE
-
批准号:2088803
-
项目类别:
-
资助金额:$49.26万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
Technetium and Rhenium in Nuclear Medicine
-
批准号:7540984
-
项目类别:
-
资助金额:$57.85万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE
-
批准号:2088805
-
项目类别:
-
资助金额:$55.18万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
THE CHEMISTRY OF TECHNETIUM RELATED TO NUCLEAR MEDICINE
-
批准号:3172754
-
项目类别:
-
资助金额:$60.54万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
Technetium and Rhenium in Nuclear Medicine
-
批准号:7186633
-
项目类别:
-
资助金额:$56.57万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE
-
批准号:6375667
-
项目类别:
-
资助金额:$48.16万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE
-
批准号:6131999
-
项目类别:
-
资助金额:$48.82万
-
财政年份:1977
-
负责人:Alun Gareth Jones
-
依托单位:
海外基金